AnaptysBio, Inc. (ANAB) |
|
18 -0.47 (-2.54%)
|
09-28 16:00 |
|
Open: |
18.47 |
Pre. Close: |
18.47 |
|
High:
|
18.56 |
Low:
|
17.77 |
|
Volume:
|
200,569 |
Market Cap:
|
478(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:48:54 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 22.22 One year: 24.03 |
| Support: |
Support1: 16.52 Support2: 13.74 |
| Resistance: |
Resistance1: 19.02 Resistance2: 20.57 |
| Pivot: |
18.65  |
| Moving Average: |
MA(5): 17.76  MA(20): 18.93
MA(100): 19.22 MA(250): 23.01 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 44.2 %D(3): 35.6 |
| RSI: |
RSI(14): 41.7 |
| 52-week: |
High: 32.43 Low: 16.52 |
| Average Vol(K): |
3-Month: 270 (K) 10-Days: 363 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANAB ] has closed above bottom band by 33.7%. Bollinger Bands are 43.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
18.57 - 18.67 |
18.67 - 18.74 |
|
Low:
|
17.55 - 17.65 |
17.65 - 17.73 |
|
Close:
|
17.85 - 18.01 |
18.01 - 18.14 |
|
Company Description |
|
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. |
Headline News |
Tue, 26 Sep 2023
Analyst Expresses Positive Outlook on Coherus BioSciences with ... - Best Stocks
Mon, 25 Sep 2023
AnaptysBio, Inc.: Analyst Coverage, Insider Trading, and Financial ... - Best Stocks
Mon, 25 Sep 2023
Argenx's 28% Surge & Promising Product Propel Investor Confidence - Nasdaq
Sat, 23 Sep 2023
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Hold ... - MarketBeat
Mon, 18 Sep 2023
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors - Yahoo Finance
Tue, 12 Sep 2023
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
1.552e+007 (%) |
|
% Held by Institutions
|
0.3 (%) |
|
Shares Short
|
4,660 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3947e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
83.4 |
|
Return on Equity (ttm)
|
-15.7 |
|
Qtrly Rev. Growth
|
1.294e+007 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-4.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-78 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
4.64e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
